Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

18.80 -0.09 (-0.48%)
Streaming Delayed Price Updated: 12:47 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 141,429
Open 18.81
Bid (Size) 18.71 (4)
Ask (Size) 18.78 (10)
Prev. Close 18.89
Today's Range 18.70 - 19.35
52wk Range 3.180 - 21.48
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025. 
Via Benzinga
Exposures Product Safety
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+31.4%
+31.4%
1 Month
+17.6%
+17.6%
3 Month
+31.8%
+31.8%
6 Month
+56.3%
+56.3%
1 Year
+422.2%
+422.2%

More News

Read More
A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts
Via Benzinga
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast
Via Benzinga
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Evaluating ETON PHARMACEUTICALS INC (NASDAQ:ETON) using Mark Minervini’s winning stock formula
Via Chartmill
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
From Eton Pharmaceuticals
Via GlobeNewswire
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know
Via Benzinga
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For March 18, 2025
Via Benzinga
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
From Eton Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Eton Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eton Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eton Pharmaceuticals, Inc. - Common Stock trade on?
Eton Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock is ETON on the Nasdaq Stock Market
What is the current price of Eton Pharmaceuticals, Inc. - Common Stock?
The current price of Eton Pharmaceuticals, Inc. - Common Stock is 18.80
When was Eton Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eton Pharmaceuticals, Inc. - Common Stock was at 06/02/25 12:47 PM ET
What is the market capitalization of Eton Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eton Pharmaceuticals, Inc. - Common Stock is 482.94M
How many shares of Eton Pharmaceuticals, Inc. - Common Stock are outstanding?
Eton Pharmaceuticals, Inc. - Common Stock has 483M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.